Dubroff: 5 reasons to pay attention to Amgen’s Otezla deal

You are here: Home > Biotech > Current Article

Dubroff: 5 reasons to pay attention to Amgen’s Otezla deal

By Henry Dubroff / Friday, August 30th, 2019 / Comments Off on Dubroff: 5 reasons to pay attention to Amgen’s Otezla deal

Henry Dubroff Merger Monday arrived on the Central Coast with a flourish on Aug. 26 when Amgen announced a $13.4 billion cash deal to buy the psoriasis drug Otezla from rival Celgene. In succeeding days, Amgen’s shares have continued to rise as analysts applauded a move that will give the Thousand Oaks-based pharma giant an…

This article is only available to Business Times subscribers

Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
Check the STATUS of your Subscription Account.